Drug
Bnt327 Dose Level 1
Bnt327 Dose Level 1: highest development phase Phase 2, developed by BioNTech. 2 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- BioNTech
Trials
| Drug | Phase | Indication |
|---|---|---|
| BNT327 Dose Level 1 (DL1) NCT06449209 | Phase 2 | Extensive-stage Small-cell Lung Cancer |
| BNT327 Dose Level 1 (DL1) NCT06449222 | Phase 2 | Locally Advanced Breast Cancer |
Latest
No recent events.
Follow Bnt327 Dose Level 1 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.